{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:40:03Z","timestamp":1784738403107,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Radioiodine (RAI) treatment for hyperthyroidism is a very common modality, chosen by physicians worldwide. The outcome of the therapy, however, is not always predictable. While rendering a patient hypo- or euthyroid is meant as a therapeutic success, the latter does not require lifelong hormonal supplementation. The aim of our study is to determine predictors of euthyreosis in patients who underwent RAI treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medical records of 144 patients who had undergone RAI therapy were examined. Laboratory and clinical data were analyzed statistically. Ultrasonography findings, such as thyroid volume, nodules\u2019 size and characteristics had been collected at the beginning of treatment and 6\u2009months after the administration of radioiodine <jats:sup>131<\/jats:sup>I<jats:sup>\u2212<\/jats:sup>. Moreover, scintigraphy results were taken into account. Multivariate logistic regression analysis model has been used to find predictors of euthyroidism after 12\u2009months of follow-up. The predictors of normal thyroid function have also been analyzed separately for patients with GD (Graves\u2019 disease) and TMNG (toxic multinodular goiter).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis showed that age (OR 1,06; 95%CI 1.025-1.096, <jats:italic>p<\/jats:italic>\u2009=\u20090,001), thyroid gland volume (OR 1,04; 95%CI 1,02-1,06; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and iodine uptake level (OR 0,952; 95%CI 0,91-0,98; <jats:italic>p<\/jats:italic>\u2009=\u20090,004) were significant factors of achieving normal thyroid function after RAI therapy. According to multivariate logistic regression analysis, in GD patients only age has been shown to be a significant factor (OR 1,06; 95%CI 1,001-1,13; <jats:italic>p<\/jats:italic>\u2009=\u20090.047), while in TMNG patients\u2019 age (OR 1,04; 95%CI 1\u20131,09; <jats:italic>p<\/jats:italic>\u2009=\u20090.048), thyroid gland volume (OR 1.038; 95%CI 1.009-1.068; <jats:italic>p<\/jats:italic>\u2009=\u20090.009) and iodine uptake level (OR 0.95; 95%CI 0.9\u20130.99; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) all have been proven to be significant predictors of achieving euthyroidism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The more advanced age, larger volume of thyroid gland and lower iodine uptake level are predictors of euthyreosis after RAI treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-020-00551-2","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T17:05:12Z","timestamp":1591117512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I\u2212: a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Albert","family":"Stachura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadetta","family":"Ka\u0142u\u017ca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Budlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Franek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/bmb\/ldr030","volume":"99","author":"MP Vanderpump","year":"2011","unstructured":"Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39\u201351.","journal-title":"Br Med Bull"},{"issue":"10","key":"551_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jama.1995.03520340064038","volume":"273","author":"PA Singer","year":"1995","unstructured":"Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of care committee, American Thyroid Association. JAMA. 1995;273(10):808\u201312.","journal-title":"JAMA."},{"issue":"12","key":"551_CR3","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1210\/jc.2012-2802","volume":"97","author":"HB Burch","year":"2012","unstructured":"Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of graves\u2019 disease. J Clin Endocrinol Metab. 2012;97(12):4549\u201358.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"551_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"1","author":"L Wartofsky","year":"1991","unstructured":"Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of graves\u2019 disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129\u201335.","journal-title":"Thyroid."},{"issue":"3","key":"551_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.6065\/apem.2014.19.3.122","volume":"19","author":"HS Lee","year":"2014","unstructured":"Lee HS, Hwang JS. The treatment of graves\u2019 disease in children and adolescents. Ann Pediatr Endocrinol Metab. 2014;19(3):122\u20136.","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"1064","key":"551_CR6","doi-asserted-by":"publisher","first-page":"20160418","DOI":"10.1259\/bjr.20160418","volume":"89","author":"J Wang","year":"2016","unstructured":"Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in graves\u2019 disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016;89(1064):20160418.","journal-title":"Br J Radiol"},{"issue":"10","key":"551_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421.","journal-title":"Thyroid."},{"issue":"6","key":"551_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2265.2007.02841.x","volume":"66","author":"AP Weetman","year":"2007","unstructured":"Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol. 2007;66(6):757\u201364.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"551_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1210\/jc.2002-020805","volume":"88","author":"WD Leslie","year":"2003","unstructured":"Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"551_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2265.1995.tb02039.x","volume":"43","author":"AE Jarl\u00f8v","year":"1995","unstructured":"Jarl\u00f8v AE, Heged\u00fcs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol. 1995;43(3):325\u20139.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"551_CR11","first-page":"1038","volume":"85","author":"A Allahabadia","year":"2000","unstructured":"Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3):1038\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"551_CR12","first-page":"3611","volume":"86","author":"A Allahabadia","year":"2001","unstructured":"Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"551_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1530\/eje.0.1410117","volume":"141","author":"B Catargi","year":"1999","unstructured":"Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of graves\u2019 disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999;141(2):117\u201321.","journal-title":"Eur J Endocrinol"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s002590100621","volume":"28","author":"D Howarth","year":"2001","unstructured":"Howarth D, et al. Determination of the optimal minimum radioiodine dose in patients with graves\u2019 disease: a clinical outcome study. Eur J Nucl Med. 2001;28:1489\u201395.","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"551_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/1450-1147.136693","volume":"12","author":"K Manohar","year":"2013","unstructured":"Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Dutta P, Bhansali A. Factors predicting treatment failure in patients treated with iodine-131 for graves\u2019 disease. World J Nucl Med. 2013;12(2):57\u201360.","journal-title":"World J Nucl Med"},{"issue":"4","key":"551_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MAJ.0000000000000288","volume":"348","author":"M Liu","year":"2014","unstructured":"Liu M, Jing D, Hu J, Yin S. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for graves\u2019 disease. Am J Med Sci. 2014;348(4):288\u201393.","journal-title":"Am J Med Sci"},{"issue":"4","key":"551_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/0972-3919.164062","volume":"30","author":"MU Zaman","year":"2015","unstructured":"Zaman MU, Fatima N, Zaman U, Sajjad Z, Zaman A, Tahseen R. Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in graves\u2019 disease. Indian J Nucl Med. 2015;30(4):309\u201313.","journal-title":"Indian J Nucl Med"},{"issue":"3","key":"551_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2265.2005.02218.x","volume":"62","author":"C Ceccarelli","year":"2005","unstructured":"Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years\u2019 retrospective study. Clin Endocrinol. 2005;62(3):331\u20135.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"551_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0038-1629865","volume":"36","author":"J Pfeilschifter","year":"1997","unstructured":"Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P. Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 gray in graves\u2019 disease. Nuklearmedizin. 1997;36(3):81\u20136.","journal-title":"Nuklearmedizin."},{"issue":"2","key":"551_CR20","first-page":"85","volume":"82","author":"A Lewis","year":"2013","unstructured":"Lewis A, Atkinson B, Bell P, Courtney H, McCance D, Mullan K, et al. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J. 2013;82(2):85\u20138.","journal-title":"Ulster Med J."},{"issue":"9","key":"551_CR21","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1210\/jc.2007-0879","volume":"92","author":"V Markovic","year":"2007","unstructured":"Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with graves\u2019 disease. J Clin Endocrinol Metab. 2007;92(9):3547\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"551_CR22","first-page":"71","volume":"49","author":"AL Blair","year":"1980","unstructured":"Blair AL, Lowe DC, Hadden DR, Weaver JA, Montgomery DA. Long term follow up of patients treated for hyperthyroidism with low dose radioactive iodine. Ulster Med J. 1980;49(1):71\u20138.","journal-title":"Ulster Med J"},{"issue":"3","key":"551_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2362.1995.tb01547.x","volume":"25","author":"H Peters","year":"1995","unstructured":"Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of graves\u2019 hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Investig. 1995;25(3):186\u201393.","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"551_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2362.2004.01349.x","volume":"34","author":"MA Walter","year":"2004","unstructured":"Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, M\u00fcller-Brand J, et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Investig. 2004;34(5):365\u201370.","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"551_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1475-097X.2006.00666.x","volume":"26","author":"US Kristoffersen","year":"2006","unstructured":"Kristoffersen US, Hesse B, Rasmussen AK, Kjaer A. Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake. Clin Physiol Funct Imaging. 2006;26(3):167\u201370.","journal-title":"Clin Physiol Funct Imaging"},{"key":"551_CR26","doi-asserted-by":"publisher","first-page":"7863867","DOI":"10.1155\/2016\/7863867","volume":"2016","author":"JA Tamatea","year":"2016","unstructured":"Tamatea JA, Conaglen JV, Elston MS. Response to radioiodine therapy for thyrotoxicosis: disparate outcomes for an indigenous population. Int J Endocrinol. 2016;2016:7863867.","journal-title":"Int J Endocrinol"},{"issue":"13","key":"551_CR27","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1245\/s10434-014-3858-4","volume":"21","author":"DF Schneider","year":"2014","unstructured":"Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014;21(13):4174\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"551_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2265.2008.03291.x","volume":"70","author":"K Boelaert","year":"2009","unstructured":"Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol. 2009;70(1):129\u201338.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"551_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2265.2004.02152.x","volume":"61","author":"S Metso","year":"2004","unstructured":"Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol. 2004;61(5):641\u20138.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"551_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1385\/ENDO:25:1:55","volume":"25","author":"C Erem","year":"2004","unstructured":"Erem C, Kandemir N, Hacihasanoglu A, Ers\u00f6z HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004;25(1):55\u201360.","journal-title":"Endocrine."},{"issue":"4","key":"551_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.5114\/aoms.2010.14476","volume":"6","author":"M Knapska-Kucharska","year":"2010","unstructured":"Knapska-Kucharska M, Oszukowska L, Lewi\u0144ski A. Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism. Arch Med Sci. 2010;6(4):611\u20136.","journal-title":"Arch Med Sci"},{"issue":"2","key":"551_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/thy.1997.7.247","volume":"7","author":"H Peters","year":"1997","unstructured":"Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of graves\u2019 hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997;7(2):247\u201351.","journal-title":"Thyroid."},{"issue":"3","key":"551_CR33","first-page":"1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Larsen PR. High dose of (131) I therapy for the treatment of hyperthyroidism caused by graves\u2019 disease. J Clin Endocrinol Metab. 2002;87(3):1073\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"551_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1507\/endocrj.51.127","volume":"51","author":"Y Yamashita","year":"2004","unstructured":"Yamashita Y, Yamane K, Tamura T, Okubo M, Kohno N. Onset age is associated with outcome of radioiodine therapy in graves\u2019 disease. Endocr J. 2004;51(2):127\u201332.","journal-title":"Endocr J"},{"issue":"6","key":"551_CR35","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1210\/er.2012-1030","volume":"33","author":"SJ Bonnema","year":"2012","unstructured":"Bonnema SJ, Heged\u00fcs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920\u201380.","journal-title":"Endocr Rev"},{"issue":"9","key":"551_CR36","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s00259-002-0877-3","volume":"29","author":"MJ Reinhardt","year":"2002","unstructured":"Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in graves\u2019 disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29(9):1118\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"551_CR37","first-page":"40","volume":"83","author":"L Chiovato","year":"1998","unstructured":"Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"551_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/eje.1.01924","volume":"153","author":"BE Jensen","year":"2005","unstructured":"Jensen BE, Bonnema SJ, Heged\u00fcs L. Glucocorticoids do not influence the effect of radioiodine therapy in graves\u2019 disease. Eur J Endocrinol. 2005;153(1):15\u201321.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"551_CR39","first-page":"1229","volume":"84","author":"O Sabri","year":"1999","unstructured":"Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in graves\u2019 disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84(4):1229\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"551_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00259-006-0092-8","volume":"33","author":"MA Walter","year":"2006","unstructured":"Walter MA, Christ-Crain M, Schindler C, M\u00fcller-Brand J, M\u00fcller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33(6):730\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"551_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-002-1101-1","volume":"30","author":"JW van Isselt","year":"2003","unstructured":"van Isselt JW, de Klerk JM, van Rijk PP, van Gils AP, Polman LJ, Kamphuis C, et al. Comparison of methods for thyroid volume estimation in patients with graves\u2019 disease. Eur J Nucl Med Mol Imaging. 2003;30(4):525\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"551_CR42","first-page":"87","volume":"38","author":"AE Jarl\u00f8v","year":"1991","unstructured":"Jarl\u00f8v AE, Heged\u00fcs L, Gj\u00f8rup T, Hansen JE. Accuracy of the clinical assessment of thyroid size. Dan Med Bull. 1991;38(1):87\u20139.","journal-title":"Dan Med Bull"},{"key":"551_CR43","doi-asserted-by":"publisher","first-page":"EP1351","DOI":"10.1530\/endoabs.49.EP1351","volume":"49","author":"C Machado","year":"2017","unstructured":"Machado C, Tavares P, Monteiro S, Rocha G, Silva F, Oliveira JM, et al. Outcome of radioiodine therapy in patients with hyperthyroidism. Endocr Abstr. 2017;49:EP1351. https:\/\/doi.org\/10.1530\/endoabs.49.EP1351.","journal-title":"Endocr Abstr"},{"issue":"12","key":"551_CR44","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/archinte.159.12.1364","volume":"159","author":"B Nygaard","year":"1999","unstructured":"Nygaard B, Heged\u00fcs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159(12):1364\u20138.","journal-title":"Arch Intern Med"},{"issue":"3","key":"551_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MNM.0b013e328333d303","volume":"31","author":"C Kobe","year":"2010","unstructured":"Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun. 2010;31(3):201\u20135.","journal-title":"Nucl Med Commun"},{"key":"551_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3413\/nukmed-0087","volume":"47","author":"C Kobe","year":"2008","unstructured":"Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves\u2019 disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13\u20137.","journal-title":"Nuklearmedizin"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-020-00551-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:36:17Z","timestamp":1622504177000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00551-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00551-2","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our study has been approved by the Bioethical Committee of the Medical University of Warsaw \u2013 approval No. AKBE\/245\/2019.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}